Lew Cantley (Cornell)
November 11, 2021 10:07 AM ESTUpdated 11:00 AM
R&D

Scoop: Famed can­cer re­searcher — and biotech founder — Lew Cant­ley is head­ed to Dana-Far­ber

John Carroll

Editor & Founder

Lew Cant­ley, the famed can­cer re­searcher best known for his dis­cov­ery of the PI3K path­way and his ground­break­ing work on can­cer me­tab­o­lism, is head­ed to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

BeiGene will re­brand to BeOne Med­i­cines, drop­ping name's link to Chi­na roots

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times